Novartis gene therapy for fatal childhood disease delivers strong sales during fourth quarter

[cafead]

via Zolgensma, the Novartis gene therapy for infants and the world’s most expensive medicine, continues to perform well commercially, bringing in $186 million during the fourth quarter, topping analyst expectations on Wednesday.

article source